BRINGING NOVEL siRNA DRUGS INTO THE CLINIC
- Our mission is to meet major unmet clinical needs by delivering novel safe and effective siRNA drugs.
- Our aim is to develop a pipeline of new Argonaute siRNA drugs by a sequence of collaboration with pharmaceutical partners
- Our vision is to make Argonaute a UK leader in the gene silencing field
ARGONAUTE SCIENCE
Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein.
Argonaute RNA research projects build on existing intellectual property. We show how our proprietary modification of small interfering RNA (siRNA) allows safe and effective ways to silence specific gene expression.
We use a novel method of stabilising the siRNA and thereby avoid a range of issues which have hitherto proved significant obstacles to developing siRNA drugs for use in man.
A scalable, platform-technology that reduces costs, improves safety and accelerates development timelines to treat diseases amenable to temporary gene silencing
– Anthony Parker
WHO WE ARE
EXECUTIVE LEADERSHIP TEAM
ARGO TEAM
BOARD OF DIRECTORS
- CoFounder/Chairman – Anthony Parker
- Anthony co-founded Argonaute RNA Ltd in 2015.
He is responsible for chairing meetings of the science team and co-ordinating engagement with third party research service providers.
His background is in finance and has worked for thirty years in investment banking and fund management. He has extensive experience in biotech, including as non-executive director of an immunotherapy company listed on the AIM market of the LSE.
- Anthony co-founded Argonaute RNA Ltd in 2015.
- CEO – Dr Mike Khan
- Mike is the former CMO of Silence Therapeutics plc, and has over 25 years of experience as a leader in R&D, spanning the full spectrum of preclinical, translational and clinical development. Mike is Former Head of Molecular Medicine and Associate Professor of Medicine at the University of Warwick. He also leads one of the foremost cardio metabolic clinics in the UK, based at the University Hospitals of Coventry and Warwickshire NHS Trust. He is an expert advisor to NICE and the EC and has contributed to establishing the current state of the art for treatment and prevention of cardiovascular diseases in the UK.
- CoFounder/CFO – Dr Richard Tompkins
- Richard co-founded Argonaute RNA Ltd with Anthony in 2015.
Richard leads on guiding all R&D projects from planning to implementation to meet intellectual property objectives. Formerly a Royal Marines officer, Richard has seventeen years of investment banking and consultancy experience, latterly at Citigroup and Barclays. He has a PhD in Economics from Exeter.
- Richard co-founded Argonaute RNA Ltd with Anthony in 2015.
- Non-Executive Director – Dr Johnathan Matlock
- Johnathan holds a PhD from the University of Bristol in Organic Chemistry and is a Chartered Chemist of the Royal Society of Chemistry. He was part of the science team at Ziylo which patented the molecule at the heart of a glucose responsive insulin. Ziylo was acquired in August 2018 by Novo Nordisk A/S in a staged M&A for up to £623m. Johnathan is co-founder of Science Angel Syndicate and is an active angel investor with a portfolio of 38 frontier science and technology companies.
- Non-Executive Director – Dr Nabil Al-Chalaby
- Dr Nabil has 14 years’ experience as Consultant Cardiologist in teaching hospitals and universities. His particular speciality is hypercholesterolaemia and atherosclerosis and he advises on Argonaute’s cardiovascular disease drug development pipeline.
- Non-Executive Director – Dr Ross Burn
- Ross is CEO of CatSci, which he span out of Astra Zeneca in 2010. CatSci provides chemistry R&D services for small to large pharmaceutical companies worldwide. Ross has led the collaboration with Argonaute in the development of new siRNA medicines.
- Non-Executive Director – David Ball
- David has over 25 years’ of experience in financial, including 15 years as equity portfolio manager and partner with Tudor Investment Corp. David is a Chartered Accountant, and holds undergraduate and postgraduate degrees in Engineering from Cambridge University. He represents Parkwalk on boards and has experience of taking early stage companies through from scale up funding through to acquisition.
- Non-Executive Director – Alexander Fink
- Alex is a principal at the Fink Family Office who led the last two funding rounds for Argonaute. He brings a wealth of knowledge on how to grow and scale businesses. He has helped raise over £200 million worth of fundraising since 2020, including companies such as Pupil, Curve and Bud. Alex was named as a RESI trailblazer by Property Week in 2019 and was ranked No3 in the climate change power list by Homes UK in 2020. Alex started his career in the city where he spent over 10 years as a fixed income trader advising high profile institutions and hedge funds.
INVESTORS
Argonaute RNA Ltd. is backed by a network of high net worth investors. For EIS opportunities, please contact info@argonauterna.com or use the submission form below.
CONTACT US
Argonaute RNA Ltd. is located in Bristol City Centre. Please get in touch if you need further information on our company or the scientific research it funds.
Argonaute RNA Ltd.
Science Creates (St Philips)
Albert Road
Bristol BS2 0XJ
United Kingdom
Call: +44 (0)117 974 2561
Email: info@argonauterna.com
Get directions with Google Maps